Full Press Release Details
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces FDA accepts MIUDELLA® sNDA for review, seeking to extend approved hormone-free IUD use from 3 to 6 years in the U.S.
OGN Positive Sentiment
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device
Key Takeaway: Organon has announced that the U.S. FDA has accepted for review its supplemental new drug application (sNDA) for MIUDELLA®, a hormone-free intrauterine device (IUD). The application seeks to extend the approved duration of use from 3 years to 6 years. This could provide patients with more options for long-term contraception.
Market Sentiment Analysis
POSITIVE FACTORS
- FDA acceptance of MIUDELLA® sNDA for review.
- Potential extension of hormone-free IUD use from 3 to 6 years.
- Increased options for patients seeking hormone-free contraception.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+130%
120-day peak, hindsight
Typical move
3%
average across 6 past catalysts
Lead asset
MK0653, ezetimibe
Phase 3 · Hypercholesterolaemia
Frequently Asked Questions
What is MIUDELLA®?
MIUDELLA® is a hormone-free intrauterine device (IUD) developed by Organon.
What does the sNDA for MIUDELLA® propose?
The sNDA seeks to extend the approved use of MIUDELLA® from 3 years to 6 years.
Who accepted the sNDA for review?
The U.S. FDA has accepted the supplemental new drug application for review.
What is the significance of this FDA review?
This review could provide patients with longer options for hormone-free contraception.